117976-90-6|Rabeprazole sodium，≥98%|Medlife|Medlife为MCE，Selleck，麦克林，阿拉丁试剂，罗恩试剂，Sigma，安耐吉试剂，泰坦等同类产品品牌，上海现货，高性价比小分子化合物

您当前的位置：

Rabeprazole sodium

质子泵抑制剂,Rabeprazole (LY307640)钠盐是质子泵抑制剂，可抗溃疡。

目录号: PC11957 纯度: ≥98%

CAS No. :117976-90-6

商品编号	规格	价格	会员价	是否有货	数量
PC11957-10mg	10mg	¥490.00	请登录
PC11957-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥490.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Rabeprazole sodium
中文别名	雷贝拉唑钠;2-{[4-(3-甲氧基丙氧基)-3-甲基吡啶-2-基]甲亚磺酰基}-1H-苯并咪唑钠;雷贝拉唑钠盐;Rabeprazole Sodium Salt 雷贝拉唑钠盐;雷贝拉唑-D4钠盐;雷贝拉唑钠标准品;雷贝拉唑钠（质子泵抑制剂）;雷贝拉唑钠标准品(JP);雷奈酸锶;雷贝拉唑钠对照品;雷贝拉唑钠及中间体;厂家供应雷贝拉唑整套杂质
英文名称	Rabeprazole sodium
英文别名	Rebeprazole sodium;2-[[[4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE, SODIUM SALT;2-[[[4-(3-METHOXYPROPOXY)-3-METHYLPYRIDIN-2-YL]METHYL]SULFINY]-1H-BENZIMIDAZOLE SODIUM SALT;sodium 2-[[4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl]methylsulfinyl]benzoimidazole;SODIUM RABEPRAZOLE;PARIET;RABEPRAZOLE SODIUM;RABEPRAZOLE, SODIUM SALT;LY307640 sodium;Rabeprazole (sodium salt);Rabeprazole Sodium S;2-([4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole,Pariprazole;sodium,2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide;2-([4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole;Pariprazole;Parie;RABEPRAZOL SODIUM;Rabeprazole SoduiM;Dexrabeprazole SodiuM;Rabeprazole SodiuM USP;Rabeprazole sodium salt;Aciphex Sodium;LY 307640 sodium;Habeprazole Sodium;Rabeprazole sodium [USAN];E 3810;(S)-Rabeprazole Sodium Salt;DSSTox_RID_80118;DSSTox_CID_24205;2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole sodium salt;C18H20N3NaO3S;DSSTox_GSID_44205;1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt;LY307640
Cas No.	117976-90-6
分子式	C₁₈H₂₀N₃NaO₃S
分子量	381.42
包装储存	4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

生物活性

Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H/K-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux.

性状

Solid

IC50 & Target[1][2]

Pump inhibitor (PPI)
IC50: 0.3 μM (UNH)
H/K-ATPase
Apoptosis

体外研究(In Vitro)

Rabeprazole attenuates the cell viability of the human gastric cancer cells following treatment with 0.2 mM for 16 hours.
Rabeprazole completely inhibits the phosphorylation of ERK1/2 in the MKN-28 cells. The gastric cancer cell line MKN-28 is cultured in acidic culture media (pH 5.4) for 2 hours. Pretreatment with Rabeprazole (0.2 mM for 2 hours) leads to strong inhibition of ERK 1/2 phosphorylation in the MKN-28 cells.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Three gastric cancer cell lines KATO III, MKN-28 and MKN-45
Concentration:	0.2 mM
Incubation Time:	16 hours
Result:	Treatment resulted in the attenuation of viability in all cancer cell lines tested, the cell viability of the MKN-28 cells significantly decreased compared with the KATO III and MKN-45 cells, respectively.

Western Blot Analysis

Cell Line:	Three gastric cancer cell lines (KATO III, MKN-28 and MKN-45)
Concentration:	0.2 mM
Incubation Time:	Pretreatment for 2 hours
Result:	Led to strong inhibition of ERK 1/2 phosphorylation in the MKN-28 cells, but a similar effect was not observed in the KATO III and MKN-45 cells.

体内研究(In Vivo)

Rabeprazole (10 mg/kg; P.O.; every 48 h for 18 weeks) course leads to a significant decline in bone mineral density (BMD) and decreases serum calcium level and produces secondary hyperparathyroidism in female mice.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Swiss albino mice (body weight equals 18-26 g)
Dosage:	10 mg/kg
Administration:	Oral administration; every 48 h for 18 weeks
Result:	Showed significantly lower serum calcium level compared to the vehicle treated group (5.5±2.07 vs. 9.68±2.77).

运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

ClinicalTrial

参考文献

[1]. Tara A Shea, et al. Identification of Proton-Pump Inhibitor Drugs That Inhibit Trichomonas Vaginalis Uridine Nucleoside Ribohydrolase. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1080-4. [Information]

[2]. Mengli Gu, et al. Rabeprazole Exhibits Antiproliferative Effects on Human Gastric Cancer Cell Lines. Oncol Lett. 2014 Oct;8(4):1739-1744. [Information]

[3]. Aly A M Shaalan, et al. Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels. Front Pharmacol. 2020 May 13;11:583. [Information]

溶解度数据

体外研究:

H₂O : ≥ 100 mg/mL (262.18 mM)

DMSO : ≥ 48 mg/mL (125.85 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6218 mL	13.1089 mL	26.2178 mL
5 mM	0.5244 mL	2.6218 mL	5.2436 mL
10 mM	0.2622 mL	1.3109 mL	2.6218 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.45 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.45 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.45 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation